December 6, 2018

To: Jill Abrams, Esq., Vermont Assistant Attorney General

Via: Electronic Mail (AGO.DrugCosts@vermont.gov; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Report for new product introduction

Dear Ms. Abrams:

Teva Pharmaceuticals USA, Inc. ("Teva") provided a product introduction notice for Granix Vials (NDCs: 63459-0918-59 and 63459-0920-59) on November 8, 2018. The Granix vials were commercially available on Wednesday, November 7, 2018.

1. **US and international marketing and pricing plans used at launch:**
    a. These details are proprietary information and Teva. This information is neither in the public domain nor is it available publicly, and Teva declines to provide further information in accordance with 18 V.S.A. § 4637(d).

2. **Estimated volume of patients:**
    a. In the United States in 2012—91,560 adults and 16,859 children with cancer were treated at a hospital because of neutropenia.
    b. Source: https://www.cdc.gov/cancer/dcpc/research/articles/neutropenia.htm

3. **Whether the FDA granted breakthrough therapy designation or a priority review:**
    a. Teva was granted priority review

4. **For drugs acquired:**
    a. Developed by Teva (Teva acquired Sicor in 2004)

Teva provides this report consistent with its understanding and interpretation of Vermont Act 165 (18 V.S.A. § 4637) and its provisions. In providing this report, Teva does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of Vermont Act 165 (18 V.S.A.§ 4637) as it may relate to Teva or any of its affiliates now or in the future. Teva, on behalf of itself and affiliates, expressly reserves all such rights.

Sincerely,

Katie Hiett
SVP, Strategic Pricing, Contracting & Customer Operations
Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals
1090 Horsham Road, North Wales, PA 19454, USA | T: 215.591.3000 | www.tevausa.com